These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 10877516)

  • 1. Interrelationship between the pharmacokinetics and pharmacodynamics of cefaclor advanced formulation in patients with acute exacerbation of chronic bronchitis.
    Cazzola M; Di Perna F; Boveri B; Di Marco F; Diamare F; Centanni S
    J Chemother; 2000 Jun; 12(3):216-22. PubMed ID: 10877516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefaclor AF: correlation of microbiology and clinical outcome.
    Thornsberry C
    Postgrad Med J; 1992; 68 Suppl 3():S10-6. PubMed ID: 1287612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of ceftriaxone and cefixime against community-acquired respiratory tract pathogens.
    Owens RC; Tessier P; Nightingale CH; Ambrose PG; Quintiliani R; Nicolau DP
    Int J Antimicrob Agents; 2001 Jun; 17(6):483-9. PubMed ID: 11397619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre trial of cefaclor advanced formulation versus cefaclor in the treatment of acute bronchitis.
    Alanis A; Longest KA; Senetar JE; Dere WH
    Postgrad Med J; 1992; 68 Suppl 3():S24-8, discussion S29. PubMed ID: 1287614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefaclor AF versus cefaclor in acute exacerbations of chronic bronchitis.
    Grossman RF
    Postgrad Med J; 1992; 68 Suppl 3():S30-6; discussion S36-7. PubMed ID: 1287616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic and clinical comparison of cefaclor in immediate-release capsule and extended-release tablet forms.
    Cole P
    Clin Ther; 1997; 19(4):617-25; discussion 603. PubMed ID: 9377607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections.
    Bantar C; Nicola F; Fernandez Canigia L; Arenoso HJ; Soutric J; Montoto M; Blanco M; Smayevsky J; Jasovich A
    J Chemother; 2000 Jun; 12(3):223-7. PubMed ID: 10877517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
    Johnson DM; Biedenbach DJ; Beach ML; Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):99-105. PubMed ID: 10863104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic treatment failures in acute otitis media.
    Stotka JL
    Pediatr Ann; 1992 May; 21(5):272-5. PubMed ID: 1625940
    [No Abstract]   [Full Text] [Related]  

  • 10. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA; Farrell DJ; Sader HS; Jones RN
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of antimicrobial activity of Cefaclor on common respiratory tract pathogens in Pakistan.
    Ahmed A; Hafiz S; Rafiq M; Tariq N; Abdulla EM; Hussain S; Azim R; Siddiqui SJ; Awan A; Khan KZ; Fareed A
    J Pak Med Assoc; 2002 Jan; 52(1):7-11. PubMed ID: 11963587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group.
    DeAbate CA; Henry D; Bensch G; Jubran A; Chodosh S; Harper L; Tipping D; Talbot GH
    Chest; 1998 Jul; 114(1):120-30. PubMed ID: 9674458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twice daily dosage of bacampicillin in chronic bronchitis. A double-blind study.
    Davies BI; Maesen FP; Brombacher PJ; Sjövall J
    Scand J Respir Dis; 1978 Oct; 59(5):249-56. PubMed ID: 32615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
    Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
    J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PK-PD modelling of the effect of cefaclor on four different bacterial strains.
    de la Peña A; Gräbe A; Rand KH; Rehak E; Gross J; Thyroff-Friesinger U; Müller M; Derendorf H
    Int J Antimicrob Agents; 2004 Mar; 23(3):218-25. PubMed ID: 15164961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998-2001 U S Surveillance Study.
    Jacobs MR; Bajaksouzian S; Windau A; Good CE; Lin G; Pankuch GA; Appelbaum PC
    Clin Lab Med; 2004 Jun; 24(2):503-30. PubMed ID: 15177851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
    Geddes AM
    Drugs; 1991; 42 Suppl 3():34-40. PubMed ID: 1726206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acute bacterial bronchitis and pneumonia with cefaclor.
    Mogabgab WJ; Pollock B; Beville RB; Gentry LO; Jemsek JG
    Postgrad Med J; 1979; 55 Suppl 4():62-6. PubMed ID: 44908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.